Trial Activity Trends
Data updated: Jul 17, 2026
Comparing 2024-2025 vs 2020-2021 trial starts by indication
Rising Indications
+30% or more trial activity growth
Lupus Nephritis Immunology
'20
'21
'22
'23
'24
'25
'26
+320%
10→42
Lupus Immunology
'20
'21
'22
'23
'24
'25
'26
+243%
46→158
Liver Failure Hepatology
'20
'21
'22
'23
'24
'25
'26
+240%
5→17
Obesity Metabolic
'20
'21
'22
'23
'24
'25
'26
+226%
151→493
Myasthenia Gravis Immunology
'20
'21
'22
'23
'24
'25
'26
+216%
19→60
Arrhythmia Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+200%
6→18
Stroke Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+188%
94→271
NMOSD Immunology
'20
'21
'22
'23
'24
'25
'26
+183%
6→17
Immune Thrombocytopenia Rare Disease
'20
'21
'22
'23
'24
'25
'26
+169%
36→97
IgA Nephropathy Immunology
'20
'21
'22
'23
'24
'25
'26
+156%
18→46
Vitiligo Dermatology
'20
'21
'22
'23
'24
'25
'26
+142%
12→29
Bipolar Disorder CNS
'20
'21
'22
'23
'24
'25
'26
+133%
15→35
IBD Immunology
'20
'21
'22
'23
'24
'25
'26
+133%
6→14
Constipation Gastrointestinal
'20
'21
'22
'23
'24
'25
'26
+127%
11→25
SCLC Oncology
'20
'21
'22
'23
'24
'25
'26
+114%
74→158
Stable Indications
-30% to +30% change
Solid Tumor (Advanced) Oncology
'20
'21
'22
'23
'24
'25
'26
+23%
1650→2023
Non-Hodgkin Lymphoma Oncology
'20
'21
'22
'23
'24
'25
'26
+14%
996→1133
Breast Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
-1%
896→885
Prostate Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
+9%
422→458
Lung Cancer (General) Oncology
'20
'21
'22
'23
'24
'25
'26
-30%
405→284
Multiple Myeloma Oncology
'20
'21
'22
'23
'24
'25
'26
+8%
245→265
Sarcoma Oncology
'20
'21
'22
'23
'24
'25
'26
-13%
293→255
Hematologic Malignancies Oncology
'20
'21
'22
'23
'24
'25
'26
+8%
249→269
Ovarian Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
+26%
242→306
Head and Neck Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
+17%
223→261
Declining Indications
-30% or more trial activity decline
COVID-19 Infectious Disease
'20
'21
'22
'23
'24
'25
'26
-91%
1971→180
Hepatitis C Infectious Disease
'20
'21
'22
'23
'24
'25
'26
-71%
24→7
Pneumonia Respiratory
'20
'21
'22
'23
'24
'25
'26
-64%
165→59
Muscle Spasm Musculoskeletal
'20
'21
'22
'23
'24
'25
'26
-50%
8→4
Fabry Disease Rare Disease
'20
'21
'22
'23
'24
'25
'26
-50%
6→3
Myelofibrosis Oncology
'20
'21
'22
'23
'24
'25
'26
-39%
80→49
Melanoma Oncology
'20
'21
'22
'23
'24
'25
'26
-36%
394→253
Merkel Cell Carcinoma Oncology
'20
'21
'22
'23
'24
'25
'26
-35%
31→20
NASH/NAFLD Metabolic
'20
'21
'22
'23
'24
'25
'26
-34%
115→76
Opioid Use Disorder CNS
'20
'21
'22
'23
'24
'25
'26
-30%
103→72
Showing top 10 rising and declining trends
Upgrade to Pro for full trend analysis and export capabilities
See Pro FeaturesMethodology: Compares average trial starts in 2024-2025 vs 2020-2021.
Sparklines: Show trial volume 2020→2026 (left to right).